ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen.

Trial Profile

ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2009

At a glance

  • Drugs Doxorubicin; Ranpirnase
  • Indications Mesothelioma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 02 Aug 2009 Results presented at IASLC 2009.
    • 02 Jun 2009 Results were presented at ASCO 2009.
    • 28 May 2008 Primary endpoint not met; preliminary results reported in an Alfacell media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top